

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

1-50. (Cancelled)

51. (Currently amended) A purified preparation of an antibody, or an antigen binding domain thereof, which specifically binds to a murine ~~mammalian~~ RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein, wherein said murine RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
52. (Currently amended) A polyclonal antibody preparation enriched for antibodies which specifically bind to a murine ~~mammalian~~ RAPT1 protein, wherein said murine RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
53. (Currently amended) A monoclonal antibody composition including a monoclonal antibody, or an antigen binding domain thereof, which specifically binds to a murine ~~mammalian~~ RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein, wherein said murine RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
54. (Currently amended) A recombinant antibody including an antigen binding domain which specifically binds to a murine ~~mammalian~~ RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein, wherein said murine RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
55. (Currently amended) The preparation of claim 51, wherein the antibody binds to a RAPT1 protein comprising ~~having~~ an amino acid sequence ~~at least 90 percent~~ identical to

the sequence of SEQ ID No. 2 12, wherein said murine RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.

56. **(Previously presented)** The preparation of claim 55, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
57. **(Currently amended)** The preparation of claim 52, enriched for antibodies which bind to a RAPT1 protein comprising having an amino acid sequence ~~at least 90 percent~~ identical to the sequence of SEQ ID No. 2 12, wherein said murine RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
58. **(Previously presented)** The preparation of claim 57 wherein the preparation has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
59. **(Currently amended)** The preparation of claim 53, wherein the monoclonal antibody binds to a RAPT1 protein comprising having an amino acid sequence ~~at least 90 percent~~ identical to the sequence of SEQ ID No. 2 12, wherein said murine RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
60. **(Previously presented)** The preparation of claim 59, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
61. **(Currently amended)** The preparation of claim 54, wherein the antigen binding domain binds to a RAPT1 protein comprising having an amino acid sequence ~~at least 90 percent~~ identical to the sequence of SEQ ID No. 2 12, wherein said murine RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
62. **(Previously presented)** The preparation of claim 61, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.

Please add the following new claims:

63. (New) A purified preparation of an antibody, or an antigen binding domain thereof, which specifically binds to a human RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein, wherein said human RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
64. (New) A polyclonal antibody preparation enriched for antibodies which specifically bind to a human RAPT1 protein, wherein said human RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
65. (New) A monoclonal antibody composition including a monoclonal antibody, or an antigen binding domain thereof, which specifically binds to a human RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein, wherein said human RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
66. (New) A recombinant antibody including an antigen binding domain which specifically binds to a human RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein, wherein said human RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
67. (New) The preparation of claim 63, wherein the antibody binds to a RAPT1 protein comprising an amino acid sequence identical to the sequence of SEQ ID No. 12, wherein said human RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
68. (New) The preparation of claim 67, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
69. (New) The preparation of claim 64, enriched for antibodies which bind to a RAPT1 protein comprising an amino acid sequence identical to the sequence of SEQ ID No. 12,

wherein said human RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.

70. (New) The preparation of claim 69 wherein the preparation has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
71. (New) The preparation of claim 65, wherein the monoclonal antibody binds to a RAPT1 protein comprising an amino acid sequence identical to the sequence of SEQ ID No. 12, wherein said human RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
72. (New) The preparation of claim 71, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
73. (New) The preparation of claim 66, wherein the antigen binding domain binds to a RAPT1 protein comprising an amino acid sequence identical to the sequence of SEQ ID No. 12, wherein said human RAPT1 protein includes a FKBP/rapamycin binding domain that binds to an FKBP/rapamycin complex.
74. (New) The preparation of claim 73, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.